IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model
Katharine Yen(Agios Pharmaceuticals (United States)), Fang Wang(Shanghai Medical College of Fudan University), Janeta Popovici-Müller(Agios Pharmaceuticals (United States)), René M. Lemieux(Agios Pharmaceuticals (United States)), Scott A. Biller(Agios Pharmaceuticals (United States)), David P. Schenkein(Agios Pharmaceuticals (United States)), Kim Straley(Agios Pharmaceuticals (United States)), Sung Choe(Agios Pharmaceuticals (United States)), Michael Su(First Affiliated Hospital of Henan University), Yue Chen(Cedars-Sinai Medical Center), Hua Yang(China Pharmaceutical University), Samuel Agresta(Agios Pharmaceuticals (United States)), Marion Dorsch(Biogen (United States))
Cited by 13
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Substrate and Functional Diversity of Lysine Acetylation Revealed by a Proteomics Survey
|Molecular Cell|2006|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acetylation Is Indispensable for p53 Activation
|Cell|2008|828